President Claudia Sheinbaum Pardo announced a 10.48 billion peso investment as part of Plan México, a strategy aimed at strengthening the national pharmaceutical industry, ensuring sector sovereignty, and boosting the country’s economic development. The funding will come from Mexican companies Kener, Genbio, Alpharma BioGenTec, and NeolSyM, and will support the production of medicines, biotechnology, and strategic supplies.
During her “Las Mañaneras del Pueblo” press conference, Sheinbaum emphasized that these efforts will help Mexico be better prepared for future risks, such as the COVID-19 pandemic, by reducing dependence on imported supplies and promoting domestic production for both the national market and exports. “We want to strengthen domestic production not only for risk preparedness but also for the growth of our economy,” she stated.
Economy Secretary Marcelo Ebrard Casaubon highlighted that the pharmaceutical sector is a priority for increasing Mexico’s self-sufficiency in medicines and represents one of the most promising areas for economic growth. Health Secretary David Kershenobich Stalnikowitz noted that these investments will promote well-being, the development of biotechnology, and the creation of original products through research.
Among the announced investments, Kener Laboratories will allocate 5.18 billion pesos to expand its injectable manufacturing plant and triple its production capacity, with completion scheduled for February 2027. This project will create 800 direct and 2,000 indirect jobs. Genbio will invest 4 billion pesos to build the first plasma fractionation plant in Latin America; Alpharma BioGenTec will invest 800 million pesos in infrastructure and the development of biopharmaceuticals and vaccines; and NeolSyM will invest 500 million pesos in the production of raw materials and inputs, generating both direct and indirect jobs.
Through these actions, the Government of Mexico reaffirms its commitment to strengthening the pharmaceutical industry, creating specialized jobs, and fostering innovation, while consolidating the country as a key player in the sector and ensuring access to high-quality medicines for its population.
